Paul J. Hergenrother wins the George & Christine Sosnovsky Award for Cancer Research.
Timothy Fan and Paul Hergenrother have created PAC-1, a new drug to combat brain cancer.
With help from an endowed chairship, Paul Hergenrother is improving antibiotics.
- Paul Hergenrother has won the Sosnovsky Award for Cancer Research, one of the National Awards of the American Chemical Society.
- Paul Hergenrother's team reports that they now know how to build a molecular Trojan horse that can penetrate gram-negative bacteria, solving a problem that for decades has stalled the development of effective new antibiotics against these increasingly drug-resistant microbes.
- Paul Hergenrother is this year's recipient of the Innovation Transfer Award - University of Illinois.
- Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.
Paul Hergenrother is the recipient of this year's UCB-Ehrlich Award for Excellence in Medicinal Chemistry.
A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans
Paul Hergenrother, the Rinehart Professor of Chemistry, appears on the list of UIUC University Scholars named this year.
Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials.
Professor Hergenrother, Karen Morrison (graduate student), and coworkers at MIT have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.
Professor Hergenrother and coworkers report that tweaking natural products' rings and functional groups could lead to better compound libraries for drug discovery.
Vanquish Oncology, Inc.
Researchers at the University of Illinois have designed a small molecule that blocks an aberrant pathway associated with myotonic dystrophy type 1, the most common form of muscular dystrophy.